에임드바이오

0009K0KOSDAQ자연과학 및 공학 연구개발업

42.0 / 100

Reference Date: 2026-04-13

Financial Score17.5 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 31.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

AimedBio is a global biotech company specializing in the development of antibody-drug conjugate (ADC)-based anticancer therapeutics, leveraging patient-derived models and proprietary linker-payload technology. As a spin-off from Samsung Seoul Hospital, the company has achieved milestones through technology transfers and co-development agreements with global pharmaceutical firms since 2024.

Number of Employees

52people

Average Salary

69.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

440.28Industry Average 120.070.0Point

3.7x industry avg (risky)

PBR

15.97Industry Average 3.820.0Point

4.2x industry avg (risky)

ROE

5.12Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

0.37Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 6.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.0 / 4

Detailed News Sentiment

4 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 47,550Won52-week high 72,50052-week low 44,000

1-month return0.0Point

1m -31.48% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral주식매수선택권부여에관한신고2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral연결재무제표기준영업실적등에대한전망(공정공시)2026-03-26
Neutral사업보고서 (2025.12)2026-03-19
Neutral감사보고서제출2026-03-19